Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

Teva Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: YAZ®

Drug: Drospirenone/Ethinyl Estradiol (Gianvi®)

Study type

Interventional

Funder types

Industry

Identifiers

NCT01182194

R06-0631

Details and patient eligibility

About

This study was designed to compare the relative bioavailability (rate and extent of absorption) of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets with that of YAZ® Tablets (by Berlex, Inc.) following a single, oral dose (2 x 3 mg/0.02 mg tablet) in healthy, adult subjects administered under fasting conditions.

Full description

Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA Bioequivalence Statistical Methods

Enrollment

32 patients

Sex

Female

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects who were informed of the nature of the study and agreed to read, review, and sign the informed consent document prior to Period I dosing.
Subjects who completed the screening process within 28 days prior to Period I dosing.
Subjects who were healthy adult menstruating women 18 to 35 years of age, inclusive, at the time of dosing.
Subjects with a body mass index (BMI) between 19 and 30 kg/m2, inclusive, and weigh at least 110 pounds.
Subjects who were healthy as documented by the medical history, physical examination, vital sign assessments, and by general observations. The physical examination also included a gynecological exam. If the subject had completed an acceptable Pap smear and gynecological exam in the previous 12 months (prior to study Day 1) and documentation of acceptable results were provided, both were deferred. Any abnormalities/deviations from the normal range which were considered clinically relevant by the study physician and investigator were evaluated for individual cases, documented in study files, and agreed upon by the study physician and investigator prior to enrolling a volunteer in this study and for continued enrollment.
Female subjects who practiced an acceptable non-hormonal method of birth control as judged by the investigator(s) at least 14 days prior to Period I dosing and throughout the study and until 14 days after the Period II dosing. The acceptable non-hormonal birth control methods included: double barriers, non-hormonal releasing intrauterine device in place for at least 30 days prior to dosing, abstinence throughout the duration of the study, or surgically sterile for at least 6 months prior to Period I dosing.

Exclusion criteria

Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
Volunteers who report taking any oral contraceptives including estrogen and progestin combined pills and progestin only pills or patch within 28 days prior to Period I dosing, or using injectable contraceptives within 6 months of Period I dosing.
Volunteers who have ever had progestational hormone implants.
Volunteers who reported any presence of history of a clinically significant disorder involving the cardiovascular, respiratory, renal, liver, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric or epilepsy disease as determined by the clinical investigator(s).
Volunteers who reported any presence or history of migraines or severe headaches.
Volunteers who had a systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 45 or over 90 mmHg were excluded from the study.
Volunteers who had a history of thrombotic disorders or have ever had cerebrovascular accident or transient ischemic attacks.
Volunteer with a history of breast cancer or undiagnosed breast nodules, active malignancies, or undiagnosed vaginal bleeding.
Volunteers having other conditions that may be aggravated by fluid retention as determined by the principal investigator.
Volunteers who has a history of jaundice with previous use of oral contraceptives or any other kinds of hormonal contraceptives.
Volunteers whose clinical laboratory test values were outside the accepted reference range and when confirmed on re-examination were deemed to be clinically significant.
Volunteers who demonstrated a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
Volunteers who reported a history of allergic response(s) to drospirenone/ethinyl estradiol, progestin/estrogens, or related drugs.
Volunteers who reported the use of any systemic prescription medication in the 14 days prior to Period I dosing (with the exception of hormonal contraceptives).
Volunteers who reported the use of any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.
Volunteers who reported a history of clinically significant allergies including drug allergies.
Volunteers who reported a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
Volunteers who reported a history of drug or alcohol addiction or abuse within the past year.
Volunteers who demonstrated a positive drug abuse screen for the study prior to Period I dosing.
Volunteers who used tobacco products in the past 6 months.
Volunteers who reported donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects were advised not to donate blood for 4 weeks after completing the study.
Volunteers who reported donating plasma within 30 days prior to Period I dosing. All subjects were advised not to donate plasma for 4 weeks after completing the study.
Volunteers who demonstrated a positive pregnancy screen.
Volunteers who are currently breastfeeding.
Volunteers who had used within the 3 months preceding Period I dosing and vaginally administered estrogen or progestin containing products.
Any volunteer who engaged in unprotected sexual intercourse during the time interval starting at 14 days prior to the first period and until 14 days after the Period II dosing.
Volunteers who had a hysterectomy or oophorectomy.